Biofil 20

A fluoroquinolone antimicrobial agent that are gaining widespread acceptance in veterinary medicine because of their broad-spectrum activity against Gram-positive and Gram-negative aerobes, mycoplasma, Rickettsia as well as against bacteria resistant to other drugs.

• Exerts their effects by binding to and inhibiting bacterial DNA-gyrase. This enzyme is important for supercoiling of cellular DNA which is needed for bacterial DNA synthesis.
• Inhibit DNA synthesis by promoting cleavage of bacterial DNA in the DNA-enzyme complexes of DNA gyrase and type IV topoisomerase, resulting in rapid bacterial death.

• Has great action against most Gram-negative bacteria (Enterobacter, Klebsiella, Proteus, Salmonella & Escherichia coli).
• Recommended for treatment of Gram-positive bacteria (staphylococci & streptococci).
• The drug is highly recommended for pneumonia, CCRD infection & colibacillosis.
• Indicated for treatment bacterial eye infections, respiratory tract infection, cellulitis & urinary tract infections.
• The drug does not exert any detrimental effects on the immune system.

• Good oral bioavailability as reach to 110.01%, little biotransformation in liver, elimination mainly by renal excretion, low plasma protein binding and high volume of distribution.
• It was found to be more rapidly absorbed, widely distributed and more quickly eliminated than other fluoroquinolones in broilers.
• Maximal plasma concentration of 3.65 lg/mL was achieved at 1.25 h after oral administration.

• 50 gm/ Ton.B. Wt. in drinking water for 3-5 days.

• 250 gm
• sole agent grand pharma